---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031355"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:13:05.916908+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma Q3 2022 revenue $3.2M (+315% YoY); net loss narrows to $3.0M

## Summary
- Product sales and royalties $3.2M, up 315% YoY and 37% sequentially, 7th straight sequential growth.
- Net loss $3.0M ($0.12/share) vs $6.1M ($0.24/share) prior year; gross profit $2.0M vs $0.1M.
- ALKINDI SPRINKLE sales grew 183% YoY and 19% QoQ; Carglumic Acid sales up 40% QoQ.
- Acquired Betaine Anhydrous, a third FDA-approved rare disease product, expected accretive in 2023.
- Zonisade FDA approval triggered $5M milestone payment, to be recognized in Q4 2022; cash $13.4M.

## SEC filing metadata
- accession: 0001493152-22-031355
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000149315222031355/0001493152-22-031355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000149315222031355/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031355
- JSON: https://secwatch.observer/filing/0001493152-22-031355.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031355.txt

## Key facts
- Earnings Releases
  Eton Pharmaceuticals, Inc. reported third quarter ended September 30, 2022 results: revenue $3.2 million, net income Net loss of $3.0 million or $0.12 per basic and diluted share, EPS $0.12 per basic and diluted share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $3.2 million
  - Net income: Net loss of $3.0 million or $0.12 per basic and diluted share
  - EPS: $0.12 per basic and diluted share
  - Result: reported results
  source text: and Recent Business Highlights Reported seventh straight quarter of sequential growth in product sales and royalty revenue. Eton reported total third quarter 2022 revenue of $3.2 million, comprised entirely of product sales and royalty revenue, representing growth of 315% over the prior year and 37% over the second quarter of 2022. Continued strong growth in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000149315222031355/0001493152-22-031355-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.